Market Overview

Kala Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference

Share:

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company
focused on the development and commercialization of product candidates
using its proprietary mucus-penetrating particle (MPP) technology, today
announced that it will present at the 2018 Wedbush PacGrow Healthcare
Conference in New York, NY. Mark Iwicki, Chairman and Chief Executive
Officer at Kala Pharmaceuticals, will provide a corporate overview on
Wednesday, August 15, 2018 at 9:45 AM ET.

To access a live webcast and subsequent archived recording of the
presentation, please visit the "Investors & Media" section on the Kala
website at http://kalarx.com/.

About Kala

Kala is a biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary
mucus-penetrating particle (MPP) technology, with an initial focus on
the treatment of eye diseases. Kala has applied the MPP technology to a
corticosteroid designed for ocular applications, resulting in two lead
product candidates: INVELTYS™ (KPI-121 1%) for the treatment of
inflammation and pain following ocular surgery, for which an NDA has
been accepted for review by the FDA and given a target action date under
the Prescription Drug User Fee Act (PDUFA) of August 24, 2018, and
KPI-121 0.25% for the temporary relief of the signs and symptoms of dry
eye disease.

View Comments and Join the Discussion!